RKWD

ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|

Rockwood Research

ADMA

ADMA BIOLOGICS, INC.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1368514Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

i

6 of 6 reported changes in each tracked manager’s latest 13F vs its prior quarter (Q2 2026). Every change is listed — no cap.

ManagerActionShare change% chgEnding % of 13F bookPosition size

Duquesne Family Office

Q2 2026Position history →

Add+1,238,500+80.1%0.54%$23.3M

Capital Research Global Investors

Q2 2026Position history →

Trim(2,434,742)(21.8%)0.01%$73.3M

Bridgewater Associates

Q2 2026Position history →

Trim(71,049)(15.0%)0.01%$3.4M

Ashford Capital Management

Q2 2026Position history →

Trim(24,280)(6.7%)0.30%$2.8M

Motley Fool Asset Management

Q2 2026Position history →

Trim(9,653)(9.6%)0.03%$0.8M

Royce & Associates

Q2 2026Position history →

Exit(27,124)(100.0%)exited$0.2M

Changes compare each manager’s latest 13F with its prior quarter for the same CUSIP. “First observation” rows have no earlier stored filing to compare and are never counted as buys; “Split?” rows moved by a near-whole factor at an unchanged value and are treated as stock splits, not trades. Ending weight is the position after the change, not the size of the change.